Vasodilator and inotropic drugs for the treatment of chronic heart failure: Distinguishing hype from hope  by Packer, Milton
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During the past 10 years, more than 80 orally active 
vasodilator and inotropic agents have been tested in the 
clinical setting to evaluate their poEeMial utilit> in the 
treatment of chronic heart failure. Although the initial 
reports of all of these drugs suggested that each represented 
a major therapeutic advance, only three dgents-digouin, 
captopril and enalapril-have produced consistent long- 
term hemodynamic and clinical benefits in these severely ill 
patients. Most of the other drugs thet have been tested have 
not (to date) distinguished themselves from placebo therapy 
in large-scale, controlled trials, even though the$e agents 
produce hemodynamic effects that closely resemble those 
seen with digitalis and (he converting-enzyme inhibitors. 
These observations suggest that the 5emodynamic de- 
rangements that characteristically accompany the develop- 
He is the best physician who k the 
Every man know better than he hope> 
When we reviewed the advantages and disadvantage> of 
wodilator and inotropic therapy for chronic heart fadurc 5 
and 10 years ago, we appealed for caution (1.1). Although it 
was clear that a wide variety of nclvel chemical agents could 
be synthesized that had the capacity to increase contractile 
force and decrease loading conditions in the failing heart. ue 
were skeptical that most pharmacologic efforts to improve 
left ventricular performance would consistently make pa- 
tients with chronic heart failure feel better and live longer. 
We had all too ofter seen the passion and cr’Fiusiasm that 
followed the introduction of new therapeutic *gent fade 
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ment of Ieft brntricular dysfunction cannot be considered to 
he the most important patbophysiologir abnormality in 
chronic heart Mure. Although cardiac conkxtility is 
usually depressed in this disease, positiv: in&tropic agents 
do not consistently improve the clinica: status ok these 
patients.. Similarly, al!hough the s+w~k vessels are usu- 
ally mxkedly constricted, drugs that ameliorate this GLSO- 
constriction do not consistently relieve symptoms, enhance 
exerik;e capacity or prolong life. Hence, correction of the 
central hemodgnamic abnormalities seen in heart fAure 
may nut necessarily provide a rational basis for drug 
development. and future advances in therapy are likely Lo 
eboive unl> h! attempting to understand and modify the 
basic ph,siolo& derangements in !hk disorder. 
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when conrrolled investigations were carried out. We bad all 
loo frequently believed the Ioglc proposed to Fupport ;f new 
treatment %itegy. only to learn (much later) that lagicai 
approaches to therapy did nor a!ways prove to bc effective 
ones. 
During the 5 year\ since our !ast review (2). more new 
drug\ have been synthesized and evaluated for rhe treatment 
of corqqtive heart failure than during the previous NO 
years ,4t least 80 different orally active chemical entities 
have been administered to patients with heart failure to 
investigate their potential utility for the treatment of this 
condition: more than 30 additional drugs have been tested by 
the intravenous route. We now have more versatile direct- 
acting vacodllators. more selective calcium channel bloc4ers 
and longer-acting and mole potent converting-enryme inhib- 
itors than we had S year% ago. We now have the ability to 
interfere with endogennds neurohormonal syrtems at muiti- 
plc Gtes. i;ve EMU now stimulate cardiac contractility with 
po~err inotropic agents to a greater extent than we could 
previously achieve with digitalis. All of these new pharItEI- 
cologic ;lpproaches have generated a great deal of excite- 
ment and hope. Yet. it is important IO ask after a decade of 
mtenbe research and development: Have these new drugs 
;ldvanced rhc treatment of chronic heart failure? 
Table 1. Or,rl Dlrrct-Ac:.ng V:t+<jdil;btor Drugs for Chronic 
Rean Failure ---_ ~- 
Ci&alafine 
Dip~rldamolc 
Minoxidil 
valid nor useful (3). this scheme for the classification of 
direct-acting vasodilators remains in common use. 
All drugs in this class (the mono- and di- and tetranitrates 
and molsidomine) exert tneir vasodilator effects by activat- 
ing soluble guanylate cyclase and thereby increasing cyclic 
guanosine monophosphate (GMP) in vascular smooth mus- 
cle (4,5)-a mechanism of action that closely resembles that 
utilized by endogenous vasodilator substances (6). MoIsido- 
&nine differs from the nitrates in that it can stimulate guanyl- 
ate cyclase directly, whereas the organic nitrates require the 
formation of an S-nitrosothiol intermediate to activate the 
enzyme (5). The predominant venodilator action of these 
drugs derives principally from the ability of these agents to 
stimulate the production of cyclic GMP more readily in veins 
than in arteries (4). 
Hemodynamic effects. The principal short-term hemody- 
namic effect of the orai nitrates and molsidomine in chronic 
heart failure is to lower right and left ventricular filling 
pressures at rest and during exercise (7-M). About 70% of 
patients experience immediate hemodynamic improvement 
after a single dose of oral isosorbide &nitrate; the remaining 
30% show no initial response to the drug (nitrate resistance), 
perhaps related to a reduced ability of venous capacitance 
vessels to dilate in edematous states (I 1,12). These short- 
term hemodynamic benefits, if seen, are not necessarily 
sustained during long-term treatment, however. Loss of 
pharmacologic activity (nitrate tolerance) is an important 
In an attempt to answer this question, we will review the clinical problem with the use of nitrates in both ischemic 
current status of the 80 orally active vasodilator and inotro- heart discasc and congestive heart failure, the magnitude of 
pit agents that have been evaluated for use in patients with tolerance development being proportional to the frequency 
chronic Fieart failure. The drugs can be classified into three of dosing. With continuous nitrate administration (as with 
large groups: the direct-acting vasodilators, the neurohormo- intravenous or transdermal therapy), the initial effects of 
nal antagonists and the positive motropic agents. these drugs are nearly completely lost in most patients 
during long-term therapy (13,14). Such loss of efficacy, 
irect-Acting Vasodilators (Table I) 
however, can be partially or totally circumvented by inter- 
mitt-nt treatment with these drugs if doses are separated by 
These agents have been traditionally classified according at least 8 to I? h (13-16). 
to :heir dominan: site of action (arterial or venous or both) in T/W dcrvhpttxwt of nitnlte mler:rnce appears to be re- 
the peripheral circulation. Five and IO years ago, this lated to both the activation of endogenous neurohnrmonal 
classification achieved ,widespread popularity based on the systems and to a decline in the ability to these drugs to 
belief :hat the site of action of these drugs could guide the increase vascular cyclic GMP (14). Tolerant vessel!, are 
rational selection of a specific vasodilator for the individual impaired in their capacity lo form the reactive nitrosothiols 
patient with heart failure. This approach assumed that in- that are needed to stimulate guanylate cyclase (14,17). 
creases in cardiac output and decreases in left ventricular Because molsidomine acts on guanylate cyclase without the 
filling pressure were invariably linked IO dilation of the requirement of a thiol intermediate, therapy with this drug 
arterial resistance and venous capacitance vessels. respec- should be less likely to be complicated by the development 
tivyly. Accordingly, physicians were advised to treat pa- of tolerance (17). Unfortunately, there is no controlled 
tients with a low cardiac output with an arterial vasodilator long-term experience with molsidomine in patients with 
drug and patients with a high left ventricular filling pressure chronic heart failure. 
with a drug that dilated systemic veins. Although we now 
recognize that this therapeutic approach may be neither 
Clinical effects. Five double-blind placebo-controlled 
clinical trials have investigated the utility of oral isosorbide 
dimtrare t/10 mg 4 Ilmcs dally) in patient\ ivclth chronic hc;trl 
failure (7.1%21). Although i\c>xxh& dimtr,ltc prtv.!~~ccd 
some favorable cfkct~ after 1 to 3 months of irc;itm:nl rn 
most of these studies. the ~ncrcase in CYCIUVJ c,~pr~c~t> JIG 
therapy with the drug was not con~i~tcn~ly grcatcr th,tn th,lt 
seen wirh placebo and wa\ not reliably xcompanicd h) ~hc: 
relief of symptoms (19). The number of patient\ cvaiuatal m 
most of these trial\ was ~m;dl ;md the rate ofdj~cuntinuati[rrl 
of treatment was high-oflcn higher in trwtcd patient\ th,m 
in the control group (7.1821). Even when comblncd \tlih 
hydralazine, isosorbidc dinitrate failccl to improve the cllni- 
cal status or exercise tolerance of paticni\ uith chronic hcxt 
failure after 2 and 6 months of tki-apb 111). 
lnteresr in the use of nitrate\ in chronic heart fralllre haj 
been renewed by the results of the Vcteranj Admmlstrallon 
Vasodilator Heart Failure Trial (v-Hcf’TI. which reported 
that when used in combination with hydr,darine. ~~orb~de 
dinitrate (40 mg 4 times daily) could rcducc mortAit> in 
patients with mild-to-moderate symptom5 (22). The comtw 
nation of both vasodilator agents wa\ poorly tolerated in this 
study, however During the period of follow-up. Wi of 
patients had to discontinue one or l%h of !he vawdkmm 
because of side effects: al the end of 6 months. only 555 uf 
patients were taking full doses of both drugs. Because these 
side effects appea! zd to be more frequent with hydralarinc 
than with isosorbidz dinitrate and hccau~ nitrate\ (when 
used alone) have been associated with a reduced mortahty 
when administered after an acute myocardial infarction 13). 
many physicians have been tempted lo use iuosorhlde dini- 
trate alone to prolong life in chronic heart fatlure. Unfonu- 
nately, such an approach (although appealing) c,mnot be 
supported by the availabte data. The reduction in mortalit)- 
in V-HeFT was related to an increase in the left vcmricthr 
ejection fraction (24). but such an increase is more likely WI 
be seen with hydralazine than with isocorbidc dinitrate (3). 
In addition, the regression of cellular hypertrophy seen in 
patients with an idiopathic cardiomyopathy when both va- 
sodilators are combined can be achicvcd with hydralaime 
alone but not with &sol-hide dinitrate :donc (301. Con+ 
quently, the role of nitrate monotherapy in reducing morhi~l- 
ity and mortality in chronic heart failure remam\ uncerlain. 
Drugs acting independently of the calcium channel. Drug\ 
in this class (hydralorine, dihydralaLnc, cndralaLine. cadr+ 
lazine. minoxidil. Ro 12-4713. dipyridamole and pinacidil) 
act primarily to dilate ,irterial resistance vcscrl~ in paticnl\ 
with chronic heart failure t%?YL alrhough the biochemical 
mechanisms by which this va$odrtating action i\ achieved 
have not been clearly defined for most drug% in this category. 
These agents increase carrli:;c outpul ;Ind decrc,~w \y+zmrc 
vascular resistance. both at re\t and during cucrciw. It i\ not 
clear, however. thal thcsc hemodynamic cffccts can he 
ir;mL181;.xl rnio clinical hcncfilc. In Gu douhlc-hlrnd plxcho- 
~r~ntrctllcd 1 rl,ils. neither hydr;tl;l~mc (200 to 700 mg d;t~ly 1. 
~hh!~lr&~/lnt [?Oti mgdallyr nor mmovldll (IO to 20 mg dally) 
hrlLc *~llc.~~ii~ll the \vmptoms or Improved ihe cxcrci\e 
~C>ICI~I~CC r>t’p.~tient\ with chronic heart I;tiiure I?! ,Zh,j!Li3) 
IL/i! \!liW/ll ,/W ;tICJWI,sI’ irr cWY/itrC or,lpfrl llWl f;Ill!l!t 5 
iif<‘JW[‘I li l/i1 ihc.sc polrnl Wl’CiGl W\!)cfillllC!rr. jtril Iri p/V 
I//U v \r/i~~r:~c*~l YYII:~I~W~~~K Ac~rrcfrr.vl Firfl. rhc mitial hc- 
mttdin;imlc Improvemen! may rail ID bc 5ustaincd during 
long-term Irwtment (34.35). such tolerance may occur xc- 
or&ry to IL?\\ of the drug’\ direct vascdilator stTect> (3-t) or 
due to ,IctiL:ition of endogtnous vasocon&ztor mecha- 
n1~1~ th,ll llrnlt the drug’; circuiatory benefits (36). Second. 
,irtt’rlai I z~od~lalors fali ‘0 produce important dccreasej In 
left Lsntrlcufar filhng pre\5ure4 or volume\ in mo5t paticnls 
with hcitrt failure (except in the prsjence of valvular rsgur- 
gtalwft) 1X-Y); m fact. fi!hng pressure\ ma? n\e \econdart 
to the rctndsncv of some of these agents to induce sodium 
rctcntion 1: h reduction in cardiac filling pressures may be 
requirtd. however. for va\od!lalor drugs to produce long- 
Ierm ctmic,d heneftts (37). Third. treatment with artenal 
\a~od!laton I\ accompanied by d high incidence of th~bling 
Gds etTccts. most commonly headache. tachycardls. gstro- 
mtc~rmal Jiyiress and edema (72.33). These iC:lCtiOn\ may 
he KLCK cnaugh to require discontinuaIion of therapy in 20 
to !fP”; of p;riicntc 12.X). Although neurohormonal activ:l- 
tion m&l): contribute IO these three prmcipal limrtation\ of 
rhcr:\py \+irh arretial vasodilatorc. ir is uncertain if the 
concom&mt use of a neurohormonal antagonkl can potcn- 
IlilIc the hencfits and minimk the ;ldvcr\c cffect~ of therapy 
wclth these drugs. 
I-‘l,rro/tl~~l,trr,l. In theory. an arlcrial va~odih~tor drug 
could hc hcncficial in chronic heart filllure wIthout ciliaring 
vcnou\ capacilance ve\sels if it acted to lower le? vcntric- 
ul;tr filling pressure by increasing 5odmrn excrcrion. Such a 
conccpr underlies the poientlal of the selective posrsynaplic 
dopaminc (DA,) receptor agonist, fenoldopam. Short-term 
therapy \vlth oral fenoldopam is accompanied by an increase 
in cmiiac output and a decrea\c in \ystemtc vascular resist- 
ancc \+ith minimal changes in cardiac filling pre\fure5 (3S!. 
YCI. hcc,liijr: rhe drug i$ a porcnt dilator of the renal 
va~culnture. it could lower ventricular filling pressures dur- 
ing long-term therapy by potentiatine the natrluretic effects 
~ff~~midc. Preliminary analy\is ofa multicenter, double- 
blind. placcno-controilcd trial with tcnoidopam ( !!!O rng 3 
tlrnc\ &III) ) in chronic heart failure has produced encourag- 
mg I-c\uhk 139). O’lher studies. however. have r:&ed doubts 
;kout the ability of fenoldopam to exert imporlant renal 
v;\i;oditaror and natriurelic etTect\ in chronic he‘:rl failure 
(10). and Ihc long+! II hemodynamic and clinical effects of 
the drug remain incompletely defined. 
Calcium cl~annel blocking drugs. All calcium channel 
Mocking drugs exert direct dilating effects on artenal resist- 
ant: CC’IXI\ and. thus. have been the focu% :)f considerable 
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interest as potential vasodilators in the treatmc;\t oi chronic sels but are orally active and, thus, may be suitable for the 
heart failure. Like hydralazine and minoxidii, the short-term long-term therapy of patients with chronic heart failure. 
administration of several calcium charme blocking agents Ftosequinan. Flosequinan exerts balanced dilator effects 
(verapainil, nifedipine. diltiazem, nicardipine. nilsodipine. on the peripheral vasculature, but (unlike nitroprusside) the 
nitrendipine, felodipine, tsradipine and amlodipine) has been drug is effective when given orally and has a long duration of 
reported to increase cardiac output and lower systemic action, permitting once daily dosing (56). Short-term therapy 
vascular resistance in patients with left ventricular dysfunc- with flosequinan (100 to I25 mg once daily) produces in- 
tion (4147). As in the case of other arterial vasodilators, creases in cardiac output and decreases in right and left 
however, these beneficial effects on cardiac performance ventricular filling pressures that are sustained during long- 
(even when sustained during long-term therapy) have not term treatment (5657). Like other direct-acting vasodilators, 
been associated with symptomatic benefits or enhanced flosequinan can activate endogenous neurohormonal sys- 
exercise tolerance in controlled clinical trials (47-49). terns, which can (in turn) limit the efficacy of therapy (58). 
Urlforrrrnarely, hec0Nse of their inhibitory efect on cob Such neurohormonal activation with flosequinan appears to 
ciurrl Jllrx itI rke hem, calcim channel blocking dwgs be dose-related, however; if large doses (150 mg daily) are 
(unlike or/r er orteriol vasodiif7rors) cotI exerl important neg- avoided, the drug can produce long-term hemodynamic and 
alive irrolrupic eflects in patients with left ventricular dys- clinical benefits without notable increases in heart rate or 
function (50,5l)-the risk of cardiodepression being propor- plasma renin activity (5758). Preliminary results from two 
tional to the severity of the underlying disease (52). In small double-blind placebo-controlled studies have demon- 
patients with mild Ieft ventricular dysfunction, the negative strated that flosequinan can improve exercise tolerance in 
inotropic action of these drugs is modest, and cardiac patients with moderate to severe symptoms (59 and personal 
performance may improve (at least during short-term ther- communication, O’Connor P). These encouraging observa- 
apy) consequent to the ability of these drugs to dilate tions require confirmation in large scale clinical trials. 
systemic vessels (51). In contrast, in patients with severe left 
ventricular dysfunction, cardiac function may deteriorate 
despite a marked reduction in systemic vascular resistance Neurohormonal Antagonists (Table 2) 
!50,52); and this reduction may be accompanied by serious 
deleterious clinical reactions (in as many as IO to 70% of 
Although we can antagonize the systemic vasoconstric- 
patients), including the precipitation of pulmonary edema 
tion seen in chronic heart failure by the administration of 
and cardiogenic shock (46,50,53,54). Although calcium chan- 
nonspecific direct-acting vasodilator drugs, such agents do 
nel blockers may differ in their predilection to depress 
not address the cause of vasoconstriction in such patients 
cardiac contractility (53), all of these agents have been 
(for example, neurohormonal activation). Hence, there has 
implicated in adversely affecting the hemodynamic and 
been enormous interest in the development of drugs that 
clinical status of these patients. Even if these drugs are 
interfere with the formation or the action of endogenous 
tolerated during short-term therapy, long-term treatment 
vasoconstrictor hormones (angiotensin II, norepinephrine, 
may exacerbate the symptoms of heart failure by stimufating 
vasopressin and serotonin). Oral agents that interfere with 
endogenous neurohormonal systems or by producing cumu- 
the renin-angiotensin system and the sympathetic nervous 
lative cardiodepressant effects (46,49). Either of these two 
system have been available for many years and have been 
mechanisms may explain why calcium channel blocking 
extensively evaluated in chronic heart failure. In contrast, 
drugs appear to increase the mortality of patients with 
there is only limited experience with agents that block the 
congestive heart failure who have suffered a recent myocar- 
actions of vasopressin and serotonin, and these studies have 
dial infarction (55). These observations suggest that, despite 
investigated only the short-term response to the administra- 
enormous enthusiasm for these drugs in recent years, there 
tion of receptor antagonists. 
is unlikely to be a future roie for calcium channel blockers in 
the management of patients with chronic heart failure. 
Drugs 7‘hal Dilate Both Peripheral Arterid and 
Venom Vessels 
The remarkable hemodynamic and clinical benefits seen 
with intravenous nitroprusside 15 years ago launched the era 
of modern-day vasodilator therapy. Since that time, there 
has been intense interest in the development of drugs that 
dilate both arterial resistance and venous capacitance ves- 
Converting-Enzyme Inhibitors 
Pharmacologic agents are now available that can interfere 
with the renin-angiotensin system at three sites: the conver- 
sion of inactive to active renin; the conversion of angiotensin 
I to angiotensin II (catalyzed by the converting-enzyme); 
and occupancy of the angiotensin II receptor by the hor- 
mone. Of the three approaches, most of the experience in 
chronic heart failure has been with the use of the converting- 
enzyme inhibitors, Over 30 agents that inhibit the convert- 
ing-enzyme have been developed for clinical use, of which 
IACC Vol. 12. No. 5 
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Table 2. Orally Active Neurohormonal Antagonists for Chronic 
Heart Failure 
Converting-enzyme inhibitors 
Captopril 
Enalapril 
Lisinopril 
Quinapril 
Ramipril 
Cilarapril 
Perindopril 
Zofenopril 
Spirapril 
Benazapril 
Inhibitors of the sympathetic nervous system 
Central adrenergic inhibitors 
Clonidine 
Methyldopa 
Guanabenz 
Inhibitors of norepinephrine synthesis and release 
Bromocriptine 
a-methyl-p-tyrosine 
Guanethidine 
Alpha-adrenergic receptor antagonists 
Phenoxybenzamine 
Prazosin 
Trimazosin 
Terazosin 
Roxazosin 
Bunazosin 
ladoramin 
Urapidil 
Beta-adrenergic receptor antagonists 
Practolol 
AIprenolol 
Propano~ol 
Metopmlol 
Acebutolol 
Pindolol 
Bucindolol 
Xamoterol 
Serotonin antagonists 
ten-captopril, enalapril, lisinopril, quinapril, ramipril, cila- 
zapril, perindopril, zofenopril, spirapril and benazapril (6& 
64)-have been evaluated in patients with heart failure. Yet. 
only two converting-enzyme inhibitors-captopril and ena- 
laprii-have been specifically approved for use in heart 
failure by the U.S. Food and Drug Administration. All 
converting-enzyme inhibitors appear to be similar in their 
mechanism of action and in their efficacy regardless of 
differences in their chemical structure and pharmacokinetic 
properiies. There is little evidence that these drugs possess 
actions independent of their ability to block the formation of 
angiotensin II that contribute impor?antly to their favorable 
clinical effects. 
Hemodynamic effects. All converkg-enzyme inhibitors 
produce sustained hemodynaqic benefits in patients with 
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chronic heart failure. The primary circulatory effect of these 
drugs is :o reduce left ventricular filling pressure at rest and 
during exercise during!ong-term !reatment (65.65). Although 
these agents also marked decrease systemic vascular resist- 
ance. converticg-enzyme inhibitors do not produce striking 
increases in cardiac output or left ventricular ejection frac- 
tion (65.66). What mechanism can explain this unusual 
hemodynamic response? Convening-enzyme inhibitors slow 
the heart rate. do not produce important dilation of the 
pulmonary vasculature. and prevent angiotensin 11 from 
exerting its positive inotropic actions (65.67,68); all three 
effects may limit the ability of the left ventricle to respond 
favorably to a decline in loading conditions. These factors 
probably explain why hypotension occurs more frequently 
with captopril and enalapril than with other vasodilator 
drugs (2). 
Although tolerunce nwy develop Awing tretlfment with 
conserlirrR-er!zyme inhihilors (65). its occurrence is !ess 
common than with other vasodilator drugs, perhaps because 
converting-enzyme inhibitors diminish rather than activate 
endogenous neurohormonal systems (69.70). In fact. the 
long-term hemodynamic response fo captopril and enalapril 
in many patients may exceed that seen during initiation of 
treatment. Even the complete lack of any discernible short- 
term effect does not preclude long-term benefits in many 
patients (65,71). 
Clinical e&c& Converting-enzyme inhibitors produce 
short- and long-term clinical improvement in chronic heart 
failure. These benefits have now been demonstrated in a 
large number of double-blind placebo-controlled clinical 
trials (61-63.72-78) and are superior to the symptomatic 
responses seen with other vasodilator drugs (49,69.70). 
Dyspnea is relieved; exercise tolerance is prolonged; and the 
need fer hospitalization and emergency care for worsening 
heart failure is reduced (66.73). This improvement is seen in 
patients with mild, moderate and severe symptoms, whether 
or not they are treated with digitalis (66,731. Captopril and 
enalapril. however. should not be used before diuretics in 
patients with a history of fluid retention, because diuretics 
remain an essential therapeutic ingredient in such individuals 
(79). Nevertheless, the converting-enzyme inhi%;; may 
reduce the need for diuretics and potassium supplements 
(66,SO). may act to correct hyponatremia and hypokalemia 
(76,77,81), and may decrease the frequency and complexity 
of ventricular arrhythmias (66,76,773. 
Apprkmateiy 60 to 70% of patients with chronic heart 
f0Lfre improve symptomatically dttring long-term treatment 
with caplopril or enaiapril(65,73~, but it is difficult to predict 
the response to this class of drugs short of a therapeutic trial. 
Athough we might expect patients with the highest plasma 
renin activity to respond most favorably to these drugs, 
plasma renin activity predicts the immediate but not the 
long-term effects of converting-enzyme inhibition (82.83). 
Similarly. neither the pretreatment hemodynamic state nor 
1304 PACKER JACC Vol. 12. No. 5 
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the initial hemodynamic response lo converting-enzyme 
inhibition accurately presages the long-term effects of treat- 
ment (65). Among all of the variables that have been exam- 
ined, only IWO pretreatment variables appear to predict the 
cIitkal efficacy of converting-enzyme inhibitors; renal func- 
tion and mean right atrial pressure (84). In patients who have 
both a mean right atrial pressure ~12 mm Hg and a serum 
creatinine concentration > I.5 mg/dl, only 35% will improve 
symptomatically during long-term converting-enzyme inhi- 
bition. In contrast, if vaIues for both mean right atrial 
pressure and serum creatinine are low, nearly 85% of pa- 
tients will show sustained benefits. Such data support ex- 
perimental studies (85.86) that suggest that both volume 
expansion and nephrectomy can attenuate the effects of 
converting-enzyme inhibition. 
Curl~~~rrBr~-enz~~~~~ inhihir0r.r pmlortg /$ irr pcrfkrrts wirh 
clrrcmic hcrrr? ffdrvc. In the CONSENSUS Study (87). 
long-term treatment with enalapril markedly reduced the 
mortality of patients with severe (class IV) symptoms: 
available data suggest a similar beneficial effect of captopril 
on the survival of patients with more moderate symptoms 
(88,891. The mechanism by which survival is favorably 
affected during treatment with these drugs remains un- 
known, however. Both experimental and clinical studies 
(76,77,9&92) suggest that converting-enzyme inhibitors may 
prolong life by retarding the progressive cardiac dilation that 
occurs after an insult to the left ventricle and by reducing the 
frequency and complexity of life-threatening ventricular 
arrhythmias. Consequently, captopril and enalapril may 
reduce the incidence of death from progressive heart failure 
as well as decrease the incidence of sudden arrhythmic 
deaths (87.89). Regardless of the mechanism of benefi!, the 
ability of converting-enzyme inhibitors to prolong survival 
creates a compelling case for their use in all patients with 
symptoms of congestive heart failure who can tolerate 
treatment with these drugs, even if their symptoms can be 
controlled by convenlional therapy. This approach will be 
strongly supported if ongoing trials indicate an important 
role for converting-enzyme inhibitors early in the syndrome 
of heart failure to prevent progression of the underlying 
disease. 
Practical considerations. Converting-enzyme inhibitors 
are generally initialed in small doses, which are then rapidly 
increased into the therapeutic range within I to 2 weeks. 
Treatment should be continued for ~2 to 4 weeks to deter- 
mine if an individual Patient will respond favorably to 
captopril or enalapril(65): the full therapeutic effect may not 
become evident for 3 IO 6 months (73.93). 
U~rjor~rrrrn~i~, IW krrorr /i/llr~ uhorrt wirrr~ dm.ws of WI- 
i’e. finR-en;?‘rne bhihitors urc ncdcd to grotlrrc-p opliwrrl 
clinicd herre~~s in chrmic hcw~ f$lwc. Although some 
palrents may respond favorably to low doses of these drugs 
(37.5 to 75 mg daily of captopril and 5 to IO mg daily of 
enalapril), nearly all of the controlled trials that have shown 
that these agents can improve exercise tolerance or prolong 
life have employed large doses (150 to 300 mg daily of 
captopril and 20 to 40 mg daily of enalapril) (73,77,87,89). 
Similarly, although captopril is frequently prescribed in two 
divided doses and enaIapriI as a single daily dose in hyper- 
tensive patients, controlled trials in heart failure have gen- 
erally utilized thrice daily dosing for captopril and twice 
daily dosing for enalapril. The only controlled trial in chronic 
heart failure that utilized once daily dosing for enalapril 
administered a single daily dose of 40 mg (77). Although 
early data suggested that high and low doses of converting- 
enzyme inhibitors produce similar hemodynamic effects, 
preliminary data (using newer inhibitors) indicate that high 
doses may be more effective than low doses in improving 
exercise tolerance. As a result, physicians should not as- 
sume that low doses of these agents produce optimal clinical 
benefits. Particular care should be exercised when patients 
receive a converting-enzyme inhibitor with the goal of 
prolonging life. because the success of treatment (with 
respect to this end point) cannot be determined in the 
individual patient. It is possible that low doses of these drugs 
alleviate symptoms but do not prolong life, 
Adverse elbts. The three principal adverse effects of 
converting-enzyme inhibition in chronic heart failure are 
hypotension. functional renal insufficiency and potassium 
retention. Hypotension occurs primarily because of the loss 
of angiotensin’s vasoconstrictor effect on the systemic vas- 
culature and may be potentiated by the withdrawal of the 
horn 3ne’s positive inotropic effects (68). Functional renal 
insufficiency results from the loss of angiotensin’s vasocon- 
strictor effect on the efferent (postglomerular) arteriole and 
may be polentiated by the decrease in renal perfusion 
pressure (94). Potassium retention may occur from the loss 
of angiotensin’s stimulatory effect on aldosterone secretion 
and may be potentiated by a deterioration in renal function 
or by the administration of potassium supplements (95). 
F~rscviorrol red imrrfic&w~. Insofar as these adverse 
effects of converting-enzyme inhibitors are related to the 
withdrawal of angiotensin II. it is not surprising that they 
occur most frequently in patients who are most dependent 
on the renin-angiotensin system for the support of circula- 
tory homeostasis (that is. class IV hyponatremic patients) 
(82.96) and when efforts are made to block the formation of 
angiotensin II continuously (as with the use of the long- 
acting converting-enzyme inhibitors: enafapril, lisinopril and 
ramipril) (64.97.98). In patients in severe (class III and IV) 
heart failure. functional renal insufficiency develops in 20 to 
30% of patients treated with captopril and in 35 to 50% of 
patients treated with enalapril (76.77,97): nearly 40% of the 
class IV patienls enrolled in the CONSENSUS study (99) 
experienced notable increases in blood urea nitrogen with 
enalapril. In contrast, in patients with moderate (class I1 and 
111) heart failure, worsening azotemia develops in only 5% of 
patients treated with captopril and I5 to 20% of patients 
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treated with lisinopril (98). Finally, in patients with mild 
symptcms (class I and II). tbe risk of functional renal 
insufficiency is so low that there may be littlc difierence 
among available converting-enzyme inhibitors, regardless of 
their pharmacokinetic characteristics. It should be noted 
that in patients who are at high risk. hypotension and 
functional renal insuficiency occur even with very small 
doses of these agents. Hence, these side effects (once 
apparent) are generally not responsive to a reduction in the 
dose of captopril or enaiapril. Both hypotension and azote- 
mia, however, can usually be ameliorated by reducing the 
dose of concomitantly administered diuretic drugs (80) and, 
thus, can generally be managed without the need to with- 
draw treatment. 
Other lrdverse efects of corrvertitlljr-r,lr=vrne iAibi!ors 
muy be imporfunt iu iudividrrul patients. Rash and dysgeusia 
may be seen during therapy with all converting-enzyme 
inhibitors but are more frequent with captopril than with 
enalapril or lisinopril. Angioneurotic edema and cough seem 
to occur with similar frequency with all drugs of this class 
and may be related to the accumulation of tissue kinins. 
whose degradation is dependent on the converting-enzyme. 
Cough has been a particularly striking side effect in our 
recent experience with these agents (occurring in 5% of 
treated patients); it was probably overlooked during the 
early experience with these drugs in patients with class IV 
symptoms, in whom cough was likely to be attributed to the 
underlying disease. 
Conclusions. Converting-enzyme inhibitors have clearly 
emerged as a significant advance in the treatment of patients 
with chronic heart failure, but many patients fail to respond 
symptomatically to these drugs, whereas other- cannot 
tolerate therapy because of hypotensiun, renal insufficiency. 
angioneurotic edema or cough. For these reasons, new 
approaches to interfering with the renin-angiotensin gstem 
are being developed (orally-active renin inhibitors and an- 
giotensin receptor antagonists) in the hope that the deleteri- 
ous effects of angiotensin II can be selectively blocked in 
specific tissues without an accumulation of tissue kinins. 
Peripheral and Cent, 31 Adrmergk inhibirors 
Pharmacologic agents are now available (commercially or 
on an investigational basis) that can interfere with the 
sympathetic nervous system ac four sites: t) at thG level of 
central nervous system so as to inhibit sympathetic outflow 
along peripheral nerves; 2) ai the level of the postganglionic 
sympathetic nerve so a: to decrease norepinephrine synthe- 
sis and release; 3) at the level of the postsynaptic alpha- 
adrenergic receptor su as to inhibit the peripheral vasocon- 
strictor actions of the sympathetic nervous system; and 4) at 
the Level of the beta-adrenergic receptor so as to block the 
effect of Latecholamines on the failing myocardium. 
Adrenergic inhibitors acting within the central nervous 
system. Sympathetic activity can be inhibited in patients 
Nith chronic heart failure by stimulating alpha,-adrenergic 
receptors within the central nervous system (with methyl- 
dopa. clonidine and guanabenz) ~100-102). All three agents 
produc.: a notable decline in plasma norepinephrine. but ihis 
favorable neurohormonal action is not accompanied by 
important short-term hemodynamic benefits. Unlike most 
vasodilators. central alpha?-agonists act in heart failure 
primarily to reduce mean arterial pressure and heart rate 
rather than increase cardiac output ~lfit.t~2)-pmbably be- 
cause thzse agents lead to a partial withdrawal of the 
compens:ltory positive inotropic and chronotropic actions of 
the sympathetic nervous system (101). Because of these 
unfavorable short-term hemodynamic effects and because of 
the frequent occurrence of disabling sedation, there has been 
little long-‘erm experience with centrally acting agents in 
patients with chronic heart failure. 
Inhibitors of norepinephrine synthesis and release. Recent 
attempts to produce a sustained decrease Ih adrenergic 
activity in severe heart failure have focused on the postgan- 
@ionic sympathetic nerves. Two different approaches have 
been utilized. t) blockade of the synthesis of norepinephrine 
in peripheral nerves (by inhibiting tyrosine hydroxylase with 
alpha-methyl-para-tyrosine) (103,104); and 2) inhibition of 
the release of n0repinephrir.e from peripheral nerves (by 
guanethidine) or by stimulating the dopamine DA2 receptor 
(by bromocriptine) (105,106). The short-term hemodynamic 
effects of :hese agents have been highly variable (KM-106). 
but thene acute: effects may not refIect the long-term re- 
sponses to these drugs when given for weeks or months 
: 103). The true potential of this novel therapeutic approach 
remains incompletely explored. 
Alpha-adrenergic recep~ antagonists. Alpha-adrenergic 
receptor blockade constituted the first attempt by physicians 
to interfere with endogenous neurohonnonal activity in 
patients with chronic heart failure. The oral administration 
of phentolamine and phenoxybenzamine produced acute 
hemodynamic benefits in early reports (107,108); similar 
short-term benefits have been observed with the use of the 
more selective postsjnaptic alpha,-adrenergic antagonists 
(prazosin. trimazosin, terazosin, doxazosin, bunazosin) 
(109-I I I). Also included in this category are alpha,- 
rntagonists that have additional sites of antiadrenergic ac- 
tion within the central nervous system (indoramin and ura- 
pidil) (I 12.113). Unfortunately, despite a few encouraging 
studies (I IO,1 14). at least six double-blind placebo- 
controlled trials (I 12,115-l 19) have shown that alpha- 
adrenergic blocking agents are not more effective tbn 
placebo in improving symptoms or enhancing exercise tol- 
erance. In addition, large-scale controlled trials (22) have not 
been able to demonstrate any favorable effect of these agents 
on left venfricular performance or survival. 
7&e primury mechanism /imiring Ilte lrliliiy of Iong-term 
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treatment with alpha-adrenergic antagonists appears to be digitalis or converting-enzyme inhibitors, and in patients 
tAe development of long-term tolerance to the pharmaco- with and without coronary artery disease (127-131). 
logic acrions ofthese drags. Although first doses of prazosin Clinical me. Preliminary studies suggest that perhaps as 
and trimazosin produce marked short-term increases in many as 60 to 70% of patients with chronic heart faiIure may 
cardiac output and decreases in right and left ventricular benefit from long-term treatment with beta-adrenergic block- 
filling pressures, these benefits become rapidly attenuated ing drugs (127, f28), The most marked improvement has been 
during prolonged treatment (120): the rapidly of tolerance noted in patients with the most advanced heart failure 
development is variable, but a significant loss of efficacy may (lowest left ventricular ejection fraction and highest heart 
be seen after only 24 to 48 h of therapy (109). Although some rate) before therapy (127,128)-who presumably had the 
decrease in mean arterial pressure generally persists during highest pretreatment circulating levels of catecholamines. 
long-term treatment with these agents, this modest hypoten- The same patients (those with the most advanced cardiac 
sive effect is not accompanied by hemodynamic or sympto- dysfunction and highest plasma norepinephrine) are also 
matic benefits (21,22,109,112). The mechanisms underlying probably most likely to experience clinical deterioration 
the development of tolerance remain unclear, however. during initiation of treatment, however (132,133). This pat- 
Whereas some investigators (69,70. I 14) have suggested that tern of response closely resembles that seen with the con- 
reactive increases in the activity of the sympathetic nervous verting-enzyme inhibitors, which also produce the highest 
system and the renin-angiotensin system may be responsible frequency of adverse effects in patients most likely to benefit 
for the loss of initial efficacy, others (115,120) have not been from treatment (82,96,134). Fortunately, the early clinical 
able to show a persistent increase in neurohormonal activity instability seen with beta-blockers can be transient and, 
during long-term treatment, and tolerance has not been thus, as in the case of the converting-enzyme inhibitors, its 
prevented by concomitant therapy with captopril or spiro- occurrence is not necessarily a reason to withdraw treat- 
nolactone ( 120, I2 I). Recent evidence (122) suggests that ment. Yet, because of the possibility of early deterioration, 
prazosin tolerance may be related to enhanced function of 
therapy with a beta-blocker is generally begun very cau- 
the unblocked alpha,-receptors, which multiply and migrate 
tiously with very low doses (for example, 6.25 mg of 
during prazosin therapy from extrajunctional to postjunction- 
metoprolol) followed by small increments achieved gradu- 
al sites, where the alpha,-receptors assume alpha,-receptor 
ally over time. The use of a beta-blocker with intrinsic 
functions. 
sympathomimetic activity may provide an added measure of 
Beta-adrenergic receptor antagonists. In contrast to 
safety (123,135) during this critical period of dosage adjust- 
‘nearly all other ageuts that have been used to treat chronic 
ment. As with the converting-enzyme inhibitors, a favorable 
heart failure, the beta-blocking drugs do not generally pro- 
clinical response to beta-blocking agents in chronic heart 
duce immediate hemodynamic or clinical benefits in these 
Liiure is commuuiy delayed and may not become apparent 
patients (123,124). In fact, cardiovascular function may 
for 2 to 6 months. This observation may explain why 
deteriorate shortly after the initiation of beta-blockade in a 
symptoms have not improved in trials that treated patients 
fashion similar to the decline seen after the administration of 
with beta-blockers for only I month (136,137). 
other drugs (clonidine and guanethidine [ IO1 ,lOS]) that inter- 
Despite these encowaging results, the me of befa- 
fere with the positive inotropic actions of the sympathetic 
blocking drags in the management of chronic heart failure 
nervous system (123,124). Long-term therapy with beta- 
shoald be considered to be strictly investigational at the 
blocking drugs, however, appears to improve cardiac per- 
present time. Most of the efficacy trials have evaulated only 
formance, symptoms and exercise tolerance in some patients 
small numbers of patients; the true response rate remains 
with chronic heart failure-possibly by neutralizing the 
unknown and dose-response information is lacking. The 
subset of patients most likely to develop worsening heart 
deleterious effects of prolonged adrenergic activation (125). failure has not been clearly defined, and the optimal man- 
The initial encouraging (but uncontrolled) reports of the agement of such early instability has not been fully delin- 
utility of beta-blockade in this disorder (which utilized eated. Such uncertainties about the efficacy and concerns 
alprenolol, practolol, metoprolol and propranolol) (!26,I27) about the safety of this approach need to be addressed by 
have recently been confirmed in double-blind, placebo- additional controlled studies before beta-blockers can be 
controlled trials using metoprolol (50 mg 2 times daily), used with conidence in the management of chronic heart 
bucindolol (100 mg 2 times daily) and xamoterol (200 mg 2 failure. 
times daily) (128-130). Uncontrolled and controlled obser- 
vations (i27,131) have also suggested a favorable effect of 
beta-blockers on the survival of patients with chronic con- Vnsopressin and Setwfonin Antagonisfs 
gestive heart failure. These beneficial effects have been seen Both vasopressin and serotonin exert potent systemic 
with beta-blockers with and without intrinsic sympathomi- vasoconstrictor effects that may interact with other endoge- 
metic activity, in the presence or absence of treatment with nous vasoconstrictor hormones and, thus. may contribute to 
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Table 3. Orally Active Positive lnotropic Agents for Chronic 
Heart Failure 
Cyclic AMP-independent agents 
Drugs acting on sodium intlux and efllux 
Digoxin 
DPI 201-106 
Metabolic cohclon 
Taurine 
Carnitine 
Coenzyme Qlo 
Cyclic AMP-dependent agents 
Beta-adrenergic receptor agoniuts 
Ephedrine 
Prenaberol 
Denopamine (TA-064) 
Pirbuterol 
Salbutamol 
Terbulaline 
Dopaminergic receptor agonists 
LWOdO,X3 
lbopamine 
Phosphodiesterdse inlubjtors 
Amrinone 
Milrinone 
Enoximone 
lmazodan (U-914) 
Piroximone 
Cl-930 
Ro 13.6438 
OPC-8?1! 
Calcium-sensitizing agents 
Sulmazol 
Pimobendan 
AMP = adenosine monophosphate. 
the hemodynamic abnormalities seen in chronic heart fail- 
ure. The short-term administration of antagonists of the 
vascular (V,) vasopressin receptor and the MT2 receptor 
(by ketanserin) produces some favorable hemodynamic ef- 
fects in this disorder (I31140), but these benefits are gener- 
ally modest or are observed in only a minority of patients. 
These unimpressihc acute responses, however, may not 
reflect the true potential of these agents in the treatment of 
chronic heart failure-if pharmacologic inhibition of these 
hormones could be maintained for long periods of time. 
Unfortunately, this therapeutic possibility cannot be ade- 
quately investigated at the present time. because orally 
active antagonists of the vasopressin receptor are not cur- 
rently available and orally active inhibitors of the 5-HTz 
receptor may not be hemodynamically effective in patients 
with chronic heart failure (140). 
Cyclic AMP-Independent Positive Inotropic 
Agents (Table 3) 
Two classes of positive inotropic agents can be identified: 
those that increase cardiac contractility by changing the 
activity of the sodium channel or sodium pump (for example, 
digiMis) and those that act by promoting the synthesis or 
inhibiting the degradation of cyclic alenosine monophos- 
phate (AMP) (for examole. catecholamines and phosphodi- 
esterase inhibitors]. L:nlike digidis, agents that act by 
increasing cyclic AMP exert direct peripheral vasodilator 
actions in addition to their cardicstimulatory effects, but the 
relative importance of the inorropic and vasodilator actions 
of these drugs in mediating their hemodynamic benefits 
remains uncertain. 
By either promoting sodium influx or inhibiting sodium 
efflux. the positive inotropic agents in this class act to 
increase intracellular sodium in the myocardial cells. This 
effect-probably by enhancing sodium-calcium exchange- 
triggers a rise in cytosolic calcium, which in turn increases 
the contractile state of the heart. 
Digitalis glycosides. The digitalis glycosides (most com- 
monly. digoxin) exert their positive inotropic effects by 
retarding sodium efflux from the myocardial cell by inhibit- 
ing a high-affinity isoform of sodium-potassium adenosine 
triphosphatase (141); other mechanisms (including a direct 
effect on the calcium current) may also contribute to the 
action of these drugs. Of note, the toxic effects of digitalis 
may be mediated by the interaction of the drug with a 
different (low-affinity) isoform of the enzyme (141). If so, it 
should be possible to pharmacologically distinguish between 
the beneficial and deleterious effects of digitalis. This excit- 
ing possibility emerges at a propitious time. After 200 years 
oj?toniroversy and doubts about its utility and safety, there 
is at last compelling evidence that digitalis is an effective and 
well-tolerated drug in patients with chronic heart failure in 
normal sinus rhythm. 
Bet~ejcid efects. Digoxin produces immediate and sus- 
tained increases in cardiac output and left ventricular ejec- 
tion fraction and decreases in cardiac filling pressures and 
volumes in patients with chronic heart failure W.142.143); 
these favorable effects dissipate predictably when the drug is 
withdrawn (142,144). Digoxin improves exercise tolerance 
and reduces the need for diuretics, hospitalization and 
emergency care for worsening heart failure (66.143); when 
digoxin is withdrawn. the clinical status of patients deterio- 
rates (144). The utility of long-term treatment with digoxin 
(0.125 to 0.50 mg daily) in chronic heart failure has 
been demonstrated in five double-blind placebo-controlled 
trials (66.143-146); four trials enrolled only patients in 
normal sinus rhythm. These benefits have been observed 
in patients with mild, moderate and severe symptoms. but 
only if they had systolic dysfunction (as evidenced by a 
low ejection fraction, kft ventricular dilation or a third 
heart sound) (66.143-145). In contrast, digoxin appears to 
be ineffective in patients with preserved systolic function 
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or without cardiomegaly. regardless of the severity of served in clinical studies (15 I). This proarrhythmic potential 
symptoms (129,147,148). In these patients, the syndrome of has prompted the withdrawal of DPI 201-106 from clinical 
heart failure may be related to an abnormality of diastolic investigation. 
(rather than systolic) function, which might not be expected 
to respond favorably to therapy with a positive inotropic 
agent. 
Adverse eflecfs. Despite concerns about its toxicity, 
recent reports have indicated that digoxin is well tolerated 
by most patients with chronic heart failure. In fact, in 
controlled trials (6&M), patients treated with digoxin expe- 
rienced less toxicity than did patients treated with placebo, 
primarily because placebo-treated patients deteriorated 
symptomatically and required additional therapy with diuret- 
ics. In contrast to converting-enzyme inhibitors, digoxin 
does not produce symptomatic hypotension or renal insufh- 
ciency (56). In contrast to other positive inotropic agents, 
digoxin is associated with fewer episodes of palpitation and 
ventricular arrhythmia (144). The adverse effects that are 
characteristic of digitalis toxicity (gastrointestinal distress, 
ectopic cardiac rhythms and heart block) seem to occur only 
when the drug is administered in large doses, but such large 
doses are not necessary to produce hemodynamic and 
symptomatic benefits (66,144). These observations suggest 
that the therapeutic to toxic ratio for digoxin may not be as 
narrow as has been previously feared. 
We know little rrhollt the effects of digoxiu on the sm~iwd 
ofpntirnts wit/r chronic hnrt frihrrc. Retrospective analy- 
ses of trials of patients recovering from an acute myocardial 
infarction have identified digitalis therapy as a risk factor 
for enhanced mortality (149), but it is possible that this 
adverse association was related to the severity of heart 
fai!ure in treated patients and not to therapy with the drug. 
To the extent that digitalis contributes to clinical stability in 
chronic heart failure, we might even expect the drug to 
improve the long-term outcome of these patients. Formal 
trials to evaluate the impact of digitalis on survival are now 
being considered by the National Heart, Lung, and Blood 
Institute. 
Inhibitors of sodium channel inactivation. DPI 201-106 
increases cardiac contractility by promoting sodium influx 
into the myocardial cell by inhibiting inactivatl.:]: of the 
sodium channel, although the drug may also increase the 
sensitivity of the contractile proteins to caIcium (150). When 
administered to patients with chronic heart failure, DPl 
201-106 produces marked increases in cardiac output but 
minimal decreases in right and left ventricular fiiling pres- 
sures (151). These hemodynamic effects are accompanied by 
a notable prolongation of the QT, intervai-an expected 
consequence of any drug that prolongs activation of the 
sodium channel, and thereby the action potential duration. 
This electrophysiolsgic effect, however. has raised concerns 
that DPI 201-106 may predispose to serious ventricmar 
arrhythmias in patients with heart failure; a concentration- 
related increase in ventricular ectopic beats has been ob- 
Metabolic Cofactors 
hotropic Agents 
OS Positive 
Some novel approaches to the treatment of heart failure 
are designed to increase the inotropic state of the myocar- 
dium by correcting a hypothesized deficiency in the failing 
heart of a critical cofactor that is essential for normal energy 
metabolism. 
Taurine. A deficiency of taurine, the most abundant free 
amino acid in mammalian hearts, has been implicated in the 
pathogenesis of at least one form of experimental car,diomy- 
opathy, which can be successfully corrected by taurine 
therapy (152). In most cases of experimental and ctinical 
heart failure, however, the myocardial content of taurine is 
increased (153) and, thus, therapy with taurine might not be 
expected to be beneficial in this disorder. Nevertheless. 
taurine exerts positive inotropic effects that are not mediated 
by an increase in cyclic AMP or an alteration in the activity 
of sodium-potassium adenosine triphosphatase (154); it po- 
tentiates the cardiostimulatory effects of calcium and oua- 
bain in vitro; and it improves indexes of cardiac contractility 
in both experimental and clinical heart failure (153,155). One 
small controlled study (155) reported that taurine (6 g daily) 
relieved the symptoms of some patients with chronic heart 
failure; but this trial failed to carry out any objective 
assessment of the hemodynamic or clinical responses to this 
agent. 
Carr.“.. .;, _ .,. forms of familial dilated cardiomyopa- 
,&. , , .,I children ha\ been traced to a deficiency of the 
quaternary ammoniu. I compound, carnitine, which func- 
tions as an obligate cofactor in the metabolism of fatty 
acids; these patients have improved dramatically after 
treatment with oral carnitine (156). Unlike children, how- 
ever. adults with a dilated cardiomyopathy have increased 
(rather than decreased) plasma levels of camitine-the most 
marked increase being seen in patients with the most ad- 
vanced heart failure (157). In the few adults with dilated 
cardiomyopathy who have had low plasma levels of carni- 
tine. attempts to restore contractile function by prolonged 
therapy with oral carnitine have not produced clinical ben- 
efits (157). 
Coenzyme Qlo. Patients with chronic heart failure appear 
to have low myocardial tissue levels of coenzyme Q,a, an 
cssentia) cofactor for normal mitochondrial respiration (158). 
Intensive therapy with oraf coenzyme Q,a has been reported 
to improve symptoms and cardiac performance in some 
patients with severe heart failure (159). but controlled, 
objective data are lacking. 
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Cyclic AMP-Dependent Positive 
Inotropic Agents 
The drugs in this category exert positive inotropic effect\ 
and peripheral vasodilator effects by virtue of their ability to 
increase intracellular cyclic AMP. These agents can he 
further subclassified into three groups: 0 the beta-adrenerglc 
and dopaminergic agonists; 2) the phosphodiesterabe inhib- 
itors; and 3) the positive inotropic agents that increase 
intracellular cyclic AMP but also sensitize !he contractile 
apparatus to cytosolic calcium. 
Bert, -Adrenergic and Dopcminergic Agmists 
Although catechoiamine sensitivity is reduced in the 
failing human heart (NO), beta-adrenergic and dopaminergic 
receptor agonists can nevertheless produce short-term he- 
modynamic benefits in chronic heart failure by a positive 
inotropic effect (mediated by an action on beta,- and beta?- 
receptors) as well as by a peripheral dilator effect (mediated 
by an action on beta,- and dopamine [DA,]-receptors). 
Beta-adrenergic receptor agonists. The nonselective beta- 
agonist (ephedrine), the beta,-selective agonists (prenalteroi 
and denopamine) and the beta+elective agonists (pirbu- 
terol, salbutamol and terbutahne) produce short-term hemo- 
dynamic effects in chronic heart failure (l6l-1661, but these 
initial favorable responses have not been translated into 
long-term clinical benefits in controlled clinical trials. In six 
double-blind studies (162,167-171). neither prenaiterol nor 
pirbuteroi have produced changes in cardiac performance+ 
symptoms or in exercise tolerance that are different from 
those seen with placebo. This lack of benefit appears to be 
related to the development of pharmacologic tolerance dur- 
ing long-term treatment with these drugs, probably related to 
the down-regulation of beta-adrenergic receptors that fol- 
lows any prolonged exposure to catecholamines (164). Con- 
sequently, the increases in cardiac output and left ventricu- 
lar ejection fraction seen during initiation of therapy with 
prenakerol and pirbuterol are no longer apparent after 4 
weeks of continuous therapy with these drugs (162,164). 
Increments in dosage do not overcome the development of 
tolerance but frequently produce adverse reactions (palpita- 
tion, tremulousness and nausea), In addition. in some pa- 
tients, beta-agonists can exacerbate ventricular arrhythmias. 
increase myocardial oxygen consumption and provoke myo- 
cardial ischemia (161.165.172). 
As with nitroglycerin, intermittewt therapy muy provide 
the most swcessftirl meu5w of o~~erconGrl: the dewlopma5t 
of tolerrmce to bet+crdreaergic ogorrists is pcrtie5u.s with 
chronic heurt frriirrre. Such an approach may prevent beta- 
receptor down-regulation and may prolong the clinical ben- 
efits seen during the initiation of treatment ( 173.174). Unfor- 
tunately, attempts to prevent tolerance may act to sustain 
the cardiostimulatory effects of these drugs, which (in turn) 
may incrt%e the prevalence of ventricular arrhythmias and 
the risk of sudden death (175,176). A recent placebo- 
controlled trial (177) designed to evaiuate the efficacy of 
intermittent intravenous dobutamine in chronic heart failure 
wa> terminated prematurely because of a disturbing trend 
toward an increase in mortality in patients trearcd with rhe 
beta-agonist. 
Dopaminergic Receptor Agonists. Both levodopa and ibo- 
pamme interact with beta-receptor\ in the heart (mediating a 
positive inotropic effect) and with dopaminergic (DA,) re- 
ceptors in the peripheral vessels (mediating a systemic 
vasodilator effect). Both agents are prodrugs: levodopa acts 
by being converted to dopamine. and ibopamine acts by 
being converted to N-methyldopamine (epinine) (178.179). 
Both drugs produce short-term increases in cardiac output 
and decreases in systemic vascular resistance. but only 
minimal decreases in right or left ventricular filling pressure 
(178.180). In fact. cardiac filling pressures may transiently 
increase after the administration of levodopa and ibopamine 
(179-181 I. possibly secondary to an alpha-adrenergic medi- 
ated constrictor action of these drugs on systemic veins and 
puimonary arterioles (179). This constrictor effect can occa- 
sionally exacerbate the symptoms of heart failure (1811. 
Despite the owwre5we of short-term hc~mod~5w5~ic be5t- 
i$ts iri ritciny pmtients. the &~rcy cf long-tiwl trefitment 
wi/h Iewdopa turd ibop~tr~tine rrnwirrs sscertuit~. Although 
the dopaminergic action of these agents should potentiate 
the natriuretic effect of diuretics. right and left ventricular 
filling pressures do not progressively decrease during pro- 
longed therapy (179.182). Furthermore, tolerance may de- 
velop to the initial hemodynamic responses IO levodopa and 
ibopamine in a fashion similar to that seen during prolonged 
therapy with other sympathomimetic agents (179,183). Fi- 
nally. therapy with dopaminergic agonists may be compli- 
cated by gastrointestinal distress, enhanced ventriculai 
arrhythmias and myocardial ischemia (179. I82,I84). Despite 
these limitations, levodopa (4 to 6 g daily) and ibopamine 
(300 mg daily) have been reported to improve the clinical 
status of patients in uncontrolled studies ( 179.182). There are 
few objective placebo-controlled data. however. to indicate 
that these drugs can improve cardiac performance and 
exercise capacity in chronic heart failure (18.5). 
Phosphodiesternse Inhibitors 
All of the agents in this class (amrinG,.>. milrinone. 
enoximone, piroximone. imazodan. U-930, Ro 13-6438 and 
OPC-82 12) increase cardiac contractility by inhibiting the 
cyclic AMP-specific (type 111) phosphodiesterase (186). Be- 
cause myocardial levels of cyclic AMP are deficient in heart 
failure. the marked positive inotropic effect of these drugs 
seen in normal cardiac muscIe is attenuated in the failing 
myocardium (187). Nevertheless, alI of these agents produce 
short-term hemodynamic benefits in patients with chronic 
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heart failure (188-195); however, only four agents-amri- tained on digitalis and diuretics, however, the addition of 
none, enoximone, milrinone and imazodan-have been eval- milrinone (30 to 40 mg daily) failed to relieve symptoms or 
uated in large-scale. long-term controlled clinical trials. enhance exercise tolerance. In one study (2131, miliinone 
Amrinone, Oral amrinone produces favorable short- and appeared to provide some clinical benefit in patients who 
long-term hemodynamic effects in patients with chronic could be withdrawn from digoxin, but attempts fo withdraw 
heart failure (188), but the doses that are required to elicit digoxin from patients (to permit the utilization of mih-inone) 
such effects (200 mg 3 times daily) are associated with was frequently accompanied by worsening heart failure that 
numerous adverse reactions (gastrointestinal distress, liver could not be controlled by treatment with milrinone (215). 
function abnormalities, fever, myalgias and thrombocytope- As with amrinone, milrinone has been reported to increase 
nia) lhat limit the amount of drug tha! can be safely admin- the frequency and complexity of ventricular arrhythmias 
istered (196,197). Lower doses of amrinone are better toler- (218) and has been associated with hemodynamic changes 
ated, but these produce few hcmodynamic benefit: (i98). suggesting that the drug may accelerate progression of the 
Possibly because of this limitation, amrinone has not been underlying disease (219); these adverse effects have recently 
shown IO be an effective agent in the treatment of chronic been confirmed in placebo-controlled trials (213-215). Addi- 
heart failure in three placebo-controlled trials (t97,199,200). tioual large scale, multicenter trials with oral mihinone are 
In addition, several studies (188,196,201) have raised con- being conducted to clarify these concerns and to elucidate 
cems that Iong-term therapy with amrinonr can enhance the the drug’s potential role in the treatment of chronic heart 
frequency and complexity of ventricular arrhythmias, pro- failure, 
voke myocardial ischemia and accelerate progression of the Imazodan (CL914). Oral imazodan produces hemody- 
underlying disease. Because of its lack of efficacy and namic effects similar to other phosphodiesterase inhibitors 
concerns about toxicity. oral amrinone has been withdrawn (192). but a large-scale, multicenter trial failed to demon- 
from clinical investigation. &ate any beneficial effect of imazodan (4 to 20 mg daily) on 
Enoximone. Oral enoximone produces favorable short- symptoms and on exercise tolerance in patients with chronic 
term hemodynamic effects in patients with chronic hcan heart failure (Bristol J., personal communication). During 
failure, but as with amrinone, long-term therapy with high the double-blind phase of this 12 week study, however, more 
doses of enoximone (3 to 6 mg’kg 3 times daily) is accom- patients died during treatment with imazodan than during 
panied by severe adverse effects including nausea, diarrhea, treatment with placebo. Interpretation of the results of this 
liver function abnormalities, headache and thrombocytope- trial is complicated by the fact that patients with worsening 
nia (190,202-204). Fortunately, lower doses of enoximone (I symptoms were permitted to crossover from one treatment 
to 2 mg/kg per dose) are better tolerated and remain hemo- group to another. Nevertheless, because of the lack of 
dynamically effective, although side effects still occur com- efficacy and concerns about toxicity, imazodan has been 
manly (in about I5 to 25% of patients) (205,206). The withdrawn from clinical investigation by the manufacturer. 
long-term efficacy of enoximone remains uncertain, how- Conclusions. Although all of the phosphodiesterase in- 
ever. Some investigators (203,204) using high doses have hibitors produce favorable short- and long-term hemody- 
observed little sustained hemodynamic or symptomatic ben- namic effects, most of the placebo-controlled studies carried 
elit, whereas other investigators (205,206) using lower doses out to date have not been able to show that these agents can 
have been more encouraging. The preliminary results of four improve the symptoms and exercise capacity of patients 
long-term placebo-controlled trials (207-210) of enoximone with chronic heart failure. Concerns have been raised with 
in chronic heart failure have also reported mixed results. As all of the drugs in this class that long-term treatment can 
with amrinone, concerns have been raised that enoximone provoke serious ventricular arrhythmias and adversely affect 
can unfavorably Sect myocardial oxygen consumption, the course of the disease. New phosphodiesterase inhibitors 
provoke angina1 attacks (211,212) and exacerbate ventricular are being developed, but it seems unlikely that these will 
arrhythmias (203,204): such adverse cardiac effects may substantially advance the treatment of chronic heart failure. 
have contributed to some of the poor long-term clinical For example, despite encouraging uncontrolled reports with 
results with the drug (190,202-204). Large scale, multicenter piroximone (1911, there are doubts about the drug’s long- 
trials are currently in progress to clarify the efficacy and term efficacy and concerns that this drug may exacerbate 
safety of oral enoximone in chronic heart failure. ventricular arrhythmias and produce gastrointestinal side 
Milrinone. Like other phosphodiesterase inhibitors, mil- effects (220). Similarly, although there have been some 
rinone produces notable short- and long-term hemodynamic favorable reports on OPC-8212 (19% the drug has recently 
effects in many patients with chronic heart failure but does been associated with the development of agranulocytosis 
not produce rhe gastrointestinal distress, liver function ab- (221). Despite all of these limitations, the phosphodiesterase 
normalities and thrombocytopenia seen with amrinone and inhibitors may prove useful as a short-term supportive 
enoximone (189). In live double-blind, placebo-controlled measure for patients with refractory heart failure who are 
triab, (213-217) in patients with chronic heart failure main- awaiting cardiac transplantation. 
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Cakium-Srnsiiizing Positive Inotropic Agents 
Several phosphodiesterase inhibitors (such as caffeine) 
may exert their positive inotropic effects by increasing the 
sensitivity of the contractile etements to calcium ion5 rather 
than increasing the concentration of free calcium in the 
cytosol (222). These agents have particular appeal in Ihe 
treatment of heart failure, because such an action mimics the 
inotropic mechanism utilized by the ver;tricle under normal 
physiologic conditions-when it adapts its: contractile state 
to changes in sarcomere length (Frank-Starli>e effect). If 
agents could be developed to increase calcium sensitivity 
selectivity. these drugs could (in theory) stimulate the heart 
without the toxicity that might accompany a prolonged 
increar.e in inlracePular cyclic AMP or calcium (2221. 
SUILGUOI and pimobendan. The benzimidazoie deriva- 
tives, sulmazol and pimobendan, increase calcium s\--nsitiv- 
ity in isolated tissues derived from normal and failing hearts 
086,222). Neither drug accomplishes this effect selectively, 
however, and much of the inotropic action of tnese agents 
depends on their ability to increase cyclic AMP-which is 
achieved by inhibiting type II1 phosphodiesterase { 186). and 
possibly. by interfering with the guanine nuclentide binding 
protein (Gi). the inhibitory regulator of adenyl cyclase (223). 
Both sulmazol(600 mg daily) and pimobendan (20 mg daily) 
produce favorable short-term hemodynamic effects in pa- 
tients with chronic heart failure (224,223, but little is known 
about the longterm hemodynamic or clinical responses to 
these drugs. Sulmazol produces severe gastrointestinal side 
effects in many patients and has been withdrawn from 
clinical investigation because of the development of hepatic 
neoplasms in long-term toxicologic studies (226). In con- 
trast, preliminary results of a small double-blind placebo- 
controlled study with pimobendan are encouraging (227). 
and large scale trials with this drug are currently being 
planned. Like other phosphodiesterase inhibitors, however, 
concerns have been raised that these agents can exacerbate 
ventricular arrhythmias (226). Whether this proarrhythmic 
potential will limit the utility of these drugs in the manage- 
ment of patients with chronic heart failure remains un- 
known. 
Conclusions 
Most of the vasodilator and inotropic drugs that have 
been developed for the treatment of heart failure have one 
characteristic in common-they have not helped patients 
feel better or live longer. Of the 80 orally active chemical 
entities that have been clinically tested during the past IO 
years. compelling evidence is available to support the et% 
cacy and safety of only three drugs-digoxin and the con- 
verting-enzyme inhibitors, captopril and enalapril. Conse- 
quently, only these agents have been approved by the Food 
and Drug Administraticln for use in chronic heart failure. 
Enalapril iq the only drug to obtain such offisial sanction 
since our last review of the treatment of heart failure 5 years 
ago (2). For most of the 77 remaining pharmacologic agents, 
Ihe result? have been disappointing. Despite enormous en- 
thusia\m that accompanied the introduction of many novel 
vasodilators and inotropic drugs. the controlled trials com- 
pleted to date have been unable to demonstrate that most of 
these therapeutic interventions have advanced the trealment 
of chronic heart failure. 
Wlrrrt l1ir.s this e.rperience liiirght 14s fihilt clinirfrl rf- 
snr~k? The initial enthusiasm that accompanied the testing 
of mosf of the 80 drugs discussed in this review was largely 
based on reports that these agents couid produce dramatic 
shorl-term Aemodytrc~mic benefits. Cardiologists have tradi- 
tionJlly placed a great deal of emphasis on hemodynamic 
mexurements: thus. it is easy to understand why an in- 
creirse in cardiac output or decrease in cardiac filling pres- 
sures seen after a single dose of a new drug triggered 
excitement. This excitement was not readily forgotten when 
the patient was discharged from the hospital and began to 
improve symptomatically. Although such improvement was 
frequently the result of intensive medical attention and 
follow-up (rarber than of the new treatment), it was natural 
to relate the clinical bencfit5 seen during long-term therapy 
to the favorable hemodynamic effects observed in the hos- 
pital. We now understand. however, that the short-term 
hemodynamic response to a new drug tells us little about its 
long-term clinical effects and that Ihe clinical status of many 
patients with heart failure responds surprisingly well to any 
closely supervised clinical setting (placebo effect). To eluci- 
date a new drug’s true potential. its effects must be evaluated 
in long-term cc~~trolled trials. We now know that we must 
restrain our enthusiasm about a new agent until such studies 
are carried out. 
Wltcr t hm this experiertre tmghi IIS ohout hem jidrrre? 
We now realize that the altered hemodynamic state seen in 
heart failure cannot be considered to be the most important 
pathophysiologic abnormality in this disorder. Although 
cardiac contractility is depressed in most patients, positive 
inotropic drugs do not produce consistent clinical benefits. 
Similarly. although the systemic vessels are usually exces- 
sively constricted in heart failure, drugs that ameliorate this 
vasconstriction do not consistently make patients feel better 
and live longer. Progress has only been achieved when we 
have tried to modify the basic physiologic derangements in 
heart failure (228) rather than correct the hemodynamic 
abnormalitites that we can easily measure. By understanding 
why some drugs succeed and others fail, we can avoid the 
disappointments of the past and can plan more rational 
therapeutic strategies for the future. Such an approach 
provides us witb real hope that we can greatly advance the 
treatment of heart failure during the next decade. 
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